PEDIATRICS Vol. 35 No. 3 March 1965, pp. 499-501
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

SCREENING OF NEWBORN INFANTS FOR METABOLIC DISEASE

COMMITTEE ON FETUS AND NEWBORN

COMMITTEE ON FETUS AND NEWBORN

AN OPPORTUNITY to establish screening procedures for case-finding in a number of metabolic diseases now exists in the United States, because most infants are born in hospitals where appropriate screening can easily be carried out. Case-finding in the neonatal period facilitates early inauguration of therapy, genetic counseling, and improved understanding of the natural history and incidence of metabolic diseases.

The Committee on Fetus and Newborn considered four types of screening programs: (1) screening of all newborn infants, (2) screening of specific groups of neonates with increased risk of certain disorders, (3) large scale, pilot-screening programs, designed primarily for research and acquisition of knowledge about the natural history of disease, (4) screening of expectant mothers, particularly using tests of amniotic fluid.

The committee did not consider screening of older children. However, it is emphasized that a number of important diseases, e.g., Wilson's disease, cannot be detected by screening in the first few days of life.

In evaluating screening tests for specific diseases, the Committee based its recommendations on the following criteria:

1. Does the seriousness of the disorder justify screening?

2. Is therapy for the disease in question available?

3. Is there a clearly identifiable segment of the population with an increased incidence of this disease?

4. Is it possible to perform reliable screening during the first few days of life?

5. Can the screening test be performed in a routine service laboratory?

6. Is the test acceptable to the physician and to a majority of parents?

7. Is the cost of the test acceptable?




This article has been cited by other articles:


Home page
 PediatricsHome page
J. P. Brosco, L. M. Sanders, M. I. Seider, and A. C. Dunn
Adverse Medical Outcomes of Early Newborn Screening Programs for Phenylketonuria
Pediatrics, July 1, 2008; 122(1): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
B. A. Tarini
The Current Revolution in Newborn Screening: New Technology, Old Controversies
Arch Pediatr Adolesc Med, August 1, 2007; 161(8): 767 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
C. J Wilson, M. P Champion, J. E Collins, P. T Clayton, and J. V Leonard
Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis
Arch. Dis. Child., May 1, 1999; 80(5): 459 - 462.
[Abstract] [Full Text]